Millennium Pharmaceuticals and The Cleveland Clinic Foundation entered into a 3 year collaboration agreement to discover novel biomarkers useful for diagnosis, prognosis and monitoring of cardiovascular diseases such as atherosclerosis, congestive heart failure etc., and to discover drug targets for cardiovascular disease.